Testing effectiveness (Phase 2)Active Not RecruitingNCT05335941
What this trial is testing
Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
Who this might be right for
Urothelial CarcinomaMetastatic Cancer
M.D. Anderson Cancer Center 10